InvestSMART

Healius Limited (ASX:HLS)

ALERT: Price-sensitive ASX Announcement for HLS
Current share price for HLS : $0.408 -0.408 (-50%)+
Announcement
Release
18 Feb 2026 8:16AM
Price at Release
$0.815
Full Release
download
Summary
Healius Limited's half-yearly report for the period ending 31 December 2025 indicates a net comprehensive loss of $30.8 million, largely driven by a reported net loss after tax of $30.4 million. The company's revenue showed a slight increase of 3.8% compared to the previous year, reaching $688.1 million, while underlying EBITDA increased by 13.1% to $122.2 million. However, financial pressures in the pathology sector, non-indexation of the Medicare Benefits Schedule, and rising employment costs are contributing challenges. The report highlights ongoing demand for pathology services driven by an aging population and advancements in genomic diagnostics. The company reports total assets of $1,773.5 million and total liabilities of $1,216.4 million, resulting in net assets of $557.1 million.
Key Points
  • Net comprehensive loss for the period was $30.8 million.
  • Reported net loss after tax was $30.4 million.
  • Revenue increased by 3.8% to $688.1 million.
  • Underlying EBITDA increased by 13.1% to $122.2 million.
  • Financial pressures in the pathology sector due to non-indexation of Medicare Benefits Schedule.
  • Rising employment costs following Fair Work Commission decision.
  • Continued demand for pathology services driven by aging population and genomic diagnostics.
  • Total assets amounted to $1,773.5 million.
  • Total liabilities were $1,216.4 million.
  • Net assets were reported at $557.1 million.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.